Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tiotropium + olodaterol + budesonide + TQC3302
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
tiotropium + olodaterol + budesonide + TQC3302 is an investigational quadruple combination therapy being developed by Chia Tai Tianqing Pharmaceutical for the treatment of chronic obstructive pulmonary disease (COPD). The regimen integrates three established classes of respiratory medicine—tiotropium (a long-acting muscarinic antagonist or LAMA), olodaterol (a long-acting beta2-agonist or LABA), and budesonide (an inhaled corticosteroid or ICS)—with TQC3302, a novel Rho-associated protein kinase (ROCK) inhibitor. By combining these four agents, the therapy aims to achieve superior bronchodilation and more effective suppression of airway inflammation and remodeling compared to triple or dual therapies. The combination is currently being evaluated in Phase I clinical trials to assess its safety, tolerability, and pharmacokinetic profile in healthy subjects and patients with COPD.
- Other names
- TQC3302 + tiotropium + olodaterol + budesonide
02
Targets
GR (Glucocorticoid receptor)ADRB2 (β2)CHRM3 (M3)
Beyond the preview
Go deeper on tiotropium + olodaterol + budesonide + TQC3302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tiotropium + olodaterol + budesonide + TQC3302.